Sarepta Therapeutics (SRPT) Q3 2024 earnings summary

Executive summary

• Achieved total net product revenue of $430 million, a 39% increase year-over-year, with Elevidys contributing $181 million and PMO franchise $249 million.

• Total revenues grew 41% year-over-year to $467.2 million for Q3 2024, driven by strong ELEVIDYS sales and expanded label approval.

• Achieved net income of $33.6 million for Q3 2024, reversing a net loss of $40.9 million in Q3 2023.

• Maintained profitability on both GAAP and non-GAAP bases for the quarter.

• Discontinued the SRP-5051 (PPMO) development program after FDA discussions and internal risk-benefit analysis.

Financial highlights

• Q3 2024 total revenues were $467.2 million, up from $331.2 million in Q3 2023.

• Elevidys net product revenue rose to $181 million from $69 million year-over-year.

• PMO franchise net product revenue was $248.8 million, up from $240.2 million year-over-year.

• Collaboration and other revenues, mainly from Roche, were $37.4 million, up from $22.5 million.

• Cost of sales increased to $91.7 million, mainly due to Elevidys label expansion and higher volumes.

• R&D expenses rose to $224.5 million (GAAP), reflecting a $91.9 million cost for terminating a manufacturing agreement.

• SG&A expenses increased to $128.2 million (GAAP), driven by commercialization efforts and personnel costs.

• Cash and equivalents stood at $1.4 billion as of September 30, 2024.

Outlook and guidance

• Reiterated Q4 and 2025 guidance, targeting $3 billion in 2025 revenue, with two-thirds from Elevidys and one-third from PMOs.

• Long-term projections include peak year sales of $5 billion across four approved therapies.

• Expect to be sustainably profitable and cash flow positive early in 2025.

• Management expects existing cash and investments to fund operations for at least the next twelve months.

• Continued investment in manufacturing capacity and partnerships to support future growth.